SGLT2 inhibitors — a class of drugs originally developed to lower blood sugar in diabetics — are now replacing or significantly reducing the need for diuretics in a substantial number of heart failure patients. In clinical practice, between 24 and 29 percent of heart failure patients who start an SGLT2 inhibitor like empagliflozin (Jardiance) or dapagliflozin (Farxiga) are able to cut back on or stop their loop diuretics entirely. For caregivers managing a loved one with both dementia and heart failure, this shift matters enormously: fewer diuretic doses can mean fewer urgent trips to the bathroom, less dehydration risk, fewer electrolyte disturbances that worsen confusion, and a simpler medication schedule for someone who may already be struggling with pill burden.
This change is not a fringe development. As of 2025, major cardiology guidelines have formally restructured heart failure treatment around four core drug classes — SGLT2 inhibitors, ARNI (sacubitril/valsartan), beta-blockers, and mineralocorticoid receptor antagonists — pushing traditional loop diuretics like furosemide out of the central role they held for decades. The FDA also approved finerenone (Kerendia), a new type of mineralocorticoid receptor antagonist, for certain heart failure patients in July 2025, adding another option that works differently from old-school diuretics. This article walks through what these newer drugs actually do, the clinical evidence behind the shift, what it means for patients living with cognitive decline, and the practical considerations caregivers should understand when discussing treatment changes with a cardiology team.
Table of Contents
- What Are SGLT2 Inhibitors and Why Are They Replacing Diuretics in Heart Failure?
- How SGLT2 Inhibitors Reduce the Need for Loop Diuretics
- Finerenone and the New Generation of Mineralocorticoid Receptor Antagonists
- The Four Pillars of Heart Failure Treatment and What They Mean for Medication Burden
- Risks and Limitations Caregivers Should Understand
- New Diuretic Delivery Methods for Patients Who Still Need Them
- Where Heart Failure Treatment Is Heading
- Conclusion
- Frequently Asked Questions
What Are SGLT2 Inhibitors and Why Are They Replacing Diuretics in Heart Failure?
SGLT2 inhibitors block a protein in the kidneys called sodium-glucose cotransporter-2, which normally reabsorbs glucose and sodium back into the bloodstream. By blocking this transporter, the drugs cause the body to excrete excess glucose and sodium through urine — producing a mild diuretic effect without the aggressive fluid dumping that loop diuretics like furosemide cause. But the real reason cardiologists are excited about them has nothing to do with fluid removal. These drugs appear to directly protect the heart and kidneys through mechanisms that researchers are still working to fully understand, including reductions in inflammation, oxidative stress, and cardiac remodeling. The landmark trials tell a clear story. The DAPA-HF, EMPEROR-Reduced, and EMPEROR-Preserved studies demonstrated a 20 to 25 percent reduction in the combined endpoint of heart failure hospitalization or cardiovascular death compared to placebo.
The EMPA-REG OUTCOME trial found empagliflozin cut heart failure hospitalizations by 35 percent — from 4.3 percent down to 2.7 percent. A meta-analysis spanning 15 randomized controlled trials and more than 28,000 patients showed SGLT2 inhibitors reduced all-cause mortality by 14 percent and cardiovascular death by roughly 15 percent. These are disease-modifying outcomes, not just symptom relief. Loop diuretics, by contrast, have never been shown in randomized trials to reduce mortality — they manage fluid overload, but they do not change the trajectory of heart failure. The comparison matters for families dealing with dementia. A drug that reduces hospitalizations by 20 to 35 percent does not just affect the heart. Every avoided hospitalization is one fewer episode of delirium, one fewer disruption to routine, and one fewer round of the disorientation that hospital stays inflict on people with cognitive impairment.
How SGLT2 Inhibitors Reduce the Need for Loop Diuretics
The diuretic-sparing effect of SGLT2 inhibitors is now well documented, though it does not happen in every patient. In studies of outpatients with heart failure, empagliflozin reduced the mean loop diuretic dosage by approximately 50 percent in about 23 percent of patients. The EMPAG-HF study found that adding empagliflozin to standard diuretic therapy increased cumulative urine output by 25 percent over five days, meaning the existing diuretic worked more efficiently rather than requiring dose escalation. For a patient on high-dose furosemide who is constantly battling fluid retention, this kind of synergy can be the difference between stability and repeated emergency department visits. The reclassification of SGLT2 inhibitors in 2025 reinforced this shift. The American Diabetes Association now recommends them as organ-protective therapies for all patients with chronic kidney disease, heart failure, or atherosclerotic cardiovascular disease risk, regardless of whether diabetes is present.
This means a heart failure patient who has never had diabetes may now be started on dapagliflozin or empagliflozin purely for cardiac and renal protection, with the secondary benefit of reducing diuretic dependence. However, not every patient can safely reduce their diuretic. Patients with severe, decompensated heart failure who are actively volume-overloaded still need loop diuretics for acute fluid management. SGLT2 inhibitors work gradually and are not a substitute during a crisis. There is also a real risk of volume depletion and hypotension in frail, elderly patients — particularly those with dementia who may not reliably report symptoms like dizziness or thirst. Caregivers should watch for signs of dehydration, including increased confusion, dry mouth, dark urine, and unsteadiness, especially in the first few weeks after starting an SGLT2 inhibitor or reducing a diuretic dose.
Finerenone and the New Generation of Mineralocorticoid Receptor Antagonists
The FDA approved finerenone (brand name Kerendia) on July 14, 2025, via Priority Review for heart failure patients with a left ventricular ejection fraction of 40 percent or higher — covering both heart failure with preserved ejection fraction and heart failure with mildly reduced ejection fraction. This drug belongs to a different category than SGLT2 inhibitors. It is a nonsteroidal mineralocorticoid receptor antagonist, meaning it blocks the same receptor as the older drug spironolactone but without the steroidal side effects like breast tenderness and hormonal disruption that made spironolactone difficult for many patients to tolerate. The FINEARTS-HF trial, which enrolled roughly 6,000 patients over a median follow-up of 2.7 years, showed finerenone achieved a 16 percent relative risk reduction in the composite endpoint of cardiovascular death and total heart failure events. The results were published in the new England Journal of Medicine and presented at the 2024 European Society of Cardiology Congress.
For a population of patients — those with preserved ejection fraction — who have historically had very few treatment options, this represents a genuine advance. The trade-offs are real, though. In the FINEARTS-HF trial, hyperkalemia occurred in 9.7 percent of patients on finerenone compared to 4.2 percent on placebo. Hypotension was reported in 7.6 percent versus 4.7 percent, and worsening renal function in 18 percent versus 12 percent. For a dementia patient who is already on multiple medications, adding finerenone means adding another drug that requires potassium monitoring and blood pressure checks. Caregivers should be aware that elevated potassium levels can cause muscle weakness, fatigue, and cardiac arrhythmias — symptoms that can be difficult to identify in someone who cannot clearly communicate how they feel.
The Four Pillars of Heart Failure Treatment and What They Mean for Medication Burden
The 2025 guidelines now organize heart failure treatment around four foundational drug classes: SGLT2 inhibitors, ARNI (sacubitril/valsartan, sold as Entresto), beta-blockers, and mineralocorticoid receptor antagonists. When all four are optimized together, recent modeling analyses suggest heart failure mortality could be reduced by up to 60 percent. Loop diuretics like furosemide and bumetanide have been formally repositioned as adjunctive therapy for symptom management rather than the treatment backbone. This is both good and complicated news for families managing heart failure alongside dementia. The good news is that these drugs address the underlying disease process rather than just chasing symptoms with escalating diuretic doses.
The complicated news is that full optimization means taking four different classes of medication, each with its own side effects, monitoring requirements, and drug interactions. For a person with moderate to advanced dementia who may resist taking pills or forget doses, achieving guideline-directed therapy may require practical trade-offs — liquid formulations, simplified dosing schedules, or frank conversations with the cardiology team about which pillars to prioritize when full optimization is not realistic. The comparison between the old and new approaches is stark. Under the older paradigm, a patient might have been managed primarily with furosemide and a beta-blocker, with dose increases in the diuretic every time fluid built up. Under the current framework, the goal is to start all four disease-modifying agents as quickly as tolerable, often at low doses, and titrate upward — reducing or eliminating diuretics as the newer drugs take effect. The EMPULSE trial showed that starting empagliflozin early during an acute heart failure hospitalization reduced subsequent hospitalizations by 35 percent and improved quality of life, suggesting that the sooner these agents are initiated, the better.
Risks and Limitations Caregivers Should Understand
None of these newer drugs are without risk, and the risks become more consequential in elderly patients with cognitive impairment. SGLT2 inhibitors increase the risk of genital fungal infections and urinary tract infections because of the excess glucose excreted in urine. In a dementia patient who wears incontinence products or who cannot maintain hygiene independently, this risk is amplified. Caregivers should monitor for signs of infection including redness, itching, unusual discharge, or sudden behavioral changes that might signal discomfort the person cannot articulate. Hypotension is a shared concern across nearly all four pillar drugs. SGLT2 inhibitors, finerenone, ARNI, and beta-blockers all lower blood pressure to varying degrees.
Stacking them can cause orthostatic hypotension — a sudden drop in blood pressure upon standing — which directly increases fall risk. Falls are already the leading cause of injury-related death in older adults with dementia. If a patient is being titrated onto multiple new heart failure medications simultaneously, caregivers should be especially vigilant about grab bars, non-slip surfaces, and monitoring for unsteadiness in the first weeks of dose adjustments. There is also an important limitation regarding evidence. Most of the major SGLT2 inhibitor and finerenone trials excluded patients with severe cognitive impairment or those unable to provide informed consent. This means the evidence base does not directly represent the dementia population. It is reasonable to extrapolate benefit, but clinicians and caregivers should acknowledge the uncertainty and weigh the goals of care — particularly in advanced dementia where quality of life and comfort may take priority over longevity-focused interventions.
New Diuretic Delivery Methods for Patients Who Still Need Them
Even as the treatment paradigm shifts away from diuretic dependence, many heart failure patients still need some level of diuretic therapy, especially during periods of fluid overload. Two recent FDA approvals have made this easier for patients who struggle with traditional oral pills. Lasix ONYU, approved on October 7, 2025, is a drug-device combination that allows patients to self-administer furosemide by subcutaneous injection at home.
For a dementia patient whose gut absorption is unreliable — a common issue in elderly patients with variable oral intake — subcutaneous delivery bypasses the gastrointestinal tract entirely and provides more predictable drug levels. The FDA also approved Enbumyst, the first intranasal loop diuretic, which delivers bumetanide via nasal spray for patients with edema from congestive heart failure. For caregivers who have struggled to get a resistant patient to swallow yet another pill, a nasal spray may offer a more manageable alternative. Both options represent recognition by the medical community that how a drug is delivered matters almost as much as what the drug does, particularly for frail elderly patients with complex care needs.
Where Heart Failure Treatment Is Heading
The trajectory is clear: heart failure treatment is moving from reactive symptom management toward proactive, disease-modifying therapy. The reclassification of SGLT2 inhibitors as organ-protective agents rather than diabetes drugs signals a broader understanding that these medications address fundamental pathological processes — inflammation, fibrosis, and neurohormonal overactivation — rather than just moving fluid. For the dementia care community, this shift should prompt more integrated conversations between cardiologists, geriatricians, and neurologists about how to optimize heart failure therapy while minimizing the cognitive burden of complex medication regimens.
The pipeline continues to evolve. As more data emerge on combining all four pillar drugs, and as new delivery methods reduce the practical barriers to medication adherence, there is genuine reason to expect better outcomes for the growing population of patients who live with both heart failure and dementia. But better outcomes depend on caregivers and clinicians having honest conversations about priorities, tolerability, and what quality of life actually means for each individual patient.
Conclusion
The replacement of diuretics as the centerpiece of heart failure treatment represents one of the most significant shifts in cardiology in the past decade. SGLT2 inhibitors like empagliflozin and dapagliflozin have demonstrated mortality reductions, fewer hospitalizations, and the ability to cut diuretic doses by half in nearly a quarter of patients. Finerenone offers new options for the preserved ejection fraction population that was previously underserved. Together with ARNI and beta-blockers, these four pillar drugs have the potential to reduce heart failure mortality by up to 60 percent when fully optimized.
For families navigating heart failure in someone with dementia, these developments are both hopeful and practically demanding. Fewer diuretic doses may mean fewer falls, less dehydration, and less confusion — but achieving optimal therapy requires careful coordination, monitoring, and willingness to adapt. Talk with the cardiology team about whether SGLT2 inhibitors or finerenone might allow a reduction in diuretic use. Ask about newer delivery options like subcutaneous furosemide or intranasal bumetanide if pill-taking is a struggle. And above all, ensure that the treatment plan reflects the patient’s goals of care, not just a guideline checklist.
Frequently Asked Questions
Can SGLT2 inhibitors be used in heart failure patients who do not have diabetes?
Yes. As of 2025, SGLT2 inhibitors are recommended as organ-protective therapy for heart failure patients regardless of diabetes status. Dapagliflozin and empagliflozin both have FDA approval specifically for heart failure independent of diabetes diagnosis.
Will my family member be able to stop their water pill entirely after starting an SGLT2 inhibitor?
Possibly, but not necessarily. Studies show that 24 to 29 percent of heart failure patients were able to reduce or discontinue loop diuretics after starting an SGLT2 inhibitor. The decision to taper or stop a diuretic should always be made by the prescribing physician based on the individual patient’s fluid status and symptoms.
Is finerenone the same as spironolactone?
No. Both block the mineralocorticoid receptor, but finerenone is a nonsteroidal agent with a different side effect profile. It avoids the hormonal effects associated with spironolactone, though it still carries risks of hyperkalemia and hypotension that require monitoring.
Are these newer heart failure drugs safe for elderly patients with dementia?
The major clinical trials largely excluded patients with severe cognitive impairment, so direct evidence in this population is limited. However, the drugs are widely used in elderly patients, and the potential benefits — particularly reduced hospitalizations and lower diuretic burden — are especially relevant for people with dementia. Close monitoring for hypotension, dehydration, and infections is essential.
What should I watch for when a dementia patient starts an SGLT2 inhibitor?
Monitor for increased urination, signs of dehydration (confusion, dry mouth, dark urine), genital or urinary tract infections, dizziness or unsteadiness from low blood pressure, and any sudden changes in behavior that might indicate discomfort. Report concerns to the prescribing physician promptly.
